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Abstract
Background: Sirolimus-eluting stents (CYPHER stents) demonstrated remarkable efficacy in
reducing restenosis rates in patients with coronary artery disease. There is a concern of sub-acute
and late stent thrombosis. Tissue factor (TF) is critical in thrombosis. This study investigated the
effect of sirolimus on TF expression and activity in cultured human vascular smooth muscle cells
(SMCs).
Methods: SMCs were cultured from human saphenous veins and aortas. Quiescent cells were
stimulated with sirolimus (0.1 – 20 ng/ml) over 24 hours. Cellular TF expression and activity
released into culture medium were measured. The effect of sirolimus on activation of mammalian
target of rapamycin (mTOR) was measured by phosphorylation of the substrate p70s6k at T389,
and activation of RhoA was measured by pull-down assay.
Results: Sirolimus increased TF protein level in cultured human SMCs in a concentration and time-
dependent manner (about 2-fold, p < 0.01) reaching maximal effect at 5 ng/ml. The stimulation of
TF expression by sirolimus was associated with inhibition of basal activity of mTOR. No effects of
sirolimus on RhoA or p38mapk activation that are positive regulators of TF in vascular wall cells
were observed. The stimulation of TF expression by sirolimus (20 ng/ml) was prevented by the
HMG-CoA reductase inhibitor fluvastatin (1 µmol/L). However, no increase in TF activity released
from SMC into culture medium was observed after sirolimus treatment.
Conclusion: Although sirolimus stimulates TF protein expression in human SMC associated with
inhibition of mTOR, it does not enhance TF activity released from the cells, suggesting a relatively
safe profile of CYPHER stents. The inhibition of TF expression by fluvastatin favors clinical use of
statins in patients undergoing coronary stenting.
Background
Since the first human study with sirolimus (rapamycin)-
eluting stents (Cordis CYPHER™ stent) by Sousa [1], con-
siderable promise of sirolimus-eluting stents for reducing
restenosis rates and clinical parameters was subsequently
demonstrated by several randomized clinical trials [2-7].
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has been suggested to be attributed to the blockade of
smooth muscle cell (SMC) cycle progression from G1 to S
phase via inhibition of the protein kinase, mammalian
target of rapamycin (mTOR)[8].
Despite the promising results on restenosis rates, there is
concern that drug-eluting stents may be associated with
increased thrombosis rates. Although stent thrombosis
associated with sirolimus-eluting stents has been reported
in several clinical trials, it remains a rare event and is not
higher in patients receiving bare metal stents [2-4,9,10].
Pooled analysis of clinical trials does not reveal a higher
incidence of stent thrombosis, suggesting a relative safe
profile of drug-eluting stents at least under the condition
of anti-platelet regiment [11]. However, individual case
reports generated some suspicion that drug-eluting stents
may be prone to thrombosis [12]. In a report, four cases
of late coronary thrombosis related to drug-eluting stents
were presented, all of them occurred shortly after anti-
platelet therapy was interrupted [12], and in two patients
who received both a bare metal stent and a sirolimus-elut-
ing stent, only the sirolimus-eluting stents were closed
due to thrombosis, while the bare metal stents remained
open in the same patients [12]. Based on the controversial
reports and concerns, we analyzed whether sirolimus per
se exerts some adverse effects related to thrombosis in vas-
cular cells namely smooth muscle cells.
Tissue factor (TF) plays an important role in thrombosis
and acute coronary syndromes [13]. It is the principle ini-
tiator of extrinsic coagulation pathway activating
thrombin and generating fibrin leading to thrombus for-
mation. Recent study suggests that aberrant TF expression
in the vascular wall cells plays a crucial role in triggering
intravascular thrombosis [14]. Under non-stimulated
conditions, vascular wall cells i.e. endothelial cells and
SMCs express negligible or low level of TF that can be up-
regulated by cytokines and thrombin [15-17]. Several
intracellular signal transduction mechanisms have been
demonstrated to be involved in the regulation of TF
expression. The small G-protein RhoA and the protein
kinase p38mapk are positive regulators, whereas phos-
phatidylinositol 3-kinase (PI3-K) negatively regulates TF
expression in vascular wall cells [17].
The HMG CoA reductase inhibitors or statins reduce car-
diovascular events in patients with coronary heart disease
[18]. The non-cholesterol lowering effects i.e. pleiotropic
effects of statins seem to play important roles [19]. Exper-
imental studies demonstrate that statins increase eNOS
expression in endothelial cells, inhibit TF expression in
SMC via inhibition of Rho/ROCK pathway [16,20].
Hence, the present study is aimed to investigate whether
sirolimus could promote TF expression in human SMC,
and whether this is associated with an increased TF activ-
ity. The effects of statin such as fluvastatin on TF expres-
sion in SMC were also investigated.
Methods
Materials
Sirolimus was purchased from Calbiochem (Lucerne,
Switzerland); fluvastatin was kindly provided by Novartis
(Basel, Switzerland); tumor necrosis factor-α (TNF-α) was
purchased from R & D, France); monoclonal mouse anti-
TF antibody and tissue factor activity kit were purchased
from American Diagnostica Inc (Socochim, Lausanne,
Switzerland); anti-tubulin and all the other chemicals for
immunoblotting were purchased from Sigma (Buchs,
Switzerland); anti-phospho p70s6k (T389) was from Cell
Signaling Technology. Alkaline phosphatase (AP)-conju-
gated anti-mouse IgG and BCIP/NBT substrate for AP were
from Interchim (Chemie Brunschwig AG, Basel,
Switzerland).
SMC and endothelial cell culture
SMC were isolated and cultured from human saphenous
veins [20] and human aortic SMC were kindly provided
by Dr. Therese Resink (University of Basel, Switzerland).
Endothelial cells from human umbilical veins were iso-
lated as previously described [17].
TF expression
Cells were rendered quiescent for 24 hours in DMEM con-
taining 0.2% BSA before they were treated with sirolimus
(20 ng/ml, 24 hours), a concentration which fully inhibits
mTOR/p70s6k pathway as previously shown [21]. To
study the effect of fluvastatin on sirolimus-induced TF
expression, the cells were pre-incubated with fluvastatin
(1 µmol/L) for 60 minutes. Cell lysates were prepared as
described [17]. 30 µg extracts were used for immunoblot-
ting of TF expression [17]. Tubulin expression was used to
ensure equal protein loading. Quantification was per-
formed using NIH Image-J software. TF expression was
expressed as percentage changes of the basal level.
TF activity in cell conditioned medium
2 × 10-5 cells/ml were seeded onto each dish for overnight
attachment. Cells were then rendered quiescent in phe-
nol-red free DMEM medium containing 0.2% BSA for 24
hours and then treated with sirolimus (20 ng/ml; 24
hours) as described above except that conditioned
medium was collected and TF activity was measured as
instructed by the manufacturer. Briefly, the same amount
of conditioned medium (25 µl) was incubated in the pres-
ence of Factor VIIa and Factor X for 15 minutes in a 96-
well plate, after which the substrate was added and further
incubated for another 60 minutes before the reaction was
stopped with glacial acetic acid and color reaction was
measured with a microplate reader at 405 nm. TF activityPage 2 of 7
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curve.
RhoA activation
The activation of RhoA was assessed by pull-down assay in
the cells stimulated with sirolimus (20 ng/ml) over one
hour as described [17]. Briefly, SMCs were washed with
ice-cold Tris-buffered saline and lysed in RIPA buffer (50
mmol/L Tris, pH 7.2, 1% Triton X-100, 0.5% sodium
deoxycholate, 0.1% SDS, 500 mmol/L NaCl, 10 mmol/L
MgCl2, 10 µg/ml each of leupeptin and aprotinin, and 1
mmol/L PMSF). 200 µg of cell lysates were incubated with
10 µg of GST-TRBD beads at 4°C for 60 min. The beads
were washed four times with buffer B (Tris-buffer contain-
ing 1% Triton X-100, 150 mmol/L NaCl, 10 mmol/L
MgCl2, 10 µg/ml each of leupeptin and aprotinin, and 0.1
mmol/L PMSF). Bound RhoA proteins were then detected
by immunoblotting using a monoclonal antibody against
RhoA (Santa Cruz Biotechnology). The total amount of
RhoA in cell lysates was used as a control for the cross-
comparison of RhoA activity (level of GTP-bound RhoA).
mTOR activation
mTOR activation was examined by immunoblotting
measuring p70s6k phosphorylation at T389 in quiescent
cells with or without sirolimus treatment (20 ng/ml, 1
hour). 40 µg cell extracts were subjected to 8% SDS-PAGE
and phosphorylated p70s6k was detected using anti-
phospho-p70s6k (T389) antibody. Activation of p70s6k
was calculated as ratio of phospho-p70s6k against
tubulin.
Statistic analysis
All data were expressed as mean ± SEM and one way anal-
ysis of variance (ANOVA) with Bonferroni's post-test was
used for statistical analysis. A two-tailed value of p ≤ 0.05
was considered statistically significant.
Results and discussion
Sirolimus-eluting stents have demonstrated remarkable
clinical efficacy in reducing restenosis rates in the short-to-
medium term [1-6]. There is a concern of subacute and
late stent thrombosis [22-24] although individual clinical
trials and pooled analysis of all the randomized trials
showed no evidence of increase in stent thrombosis with
drug-eluting stents as compared to the bare-metal stents
in the short-to-medium term [2-4,9,10,25]. Some clinical
experiences suggest that sirolimus-eluting stents may be
prone to thrombosis [12,22,23,26,27]. In an earlier report
[22], a case of late stent thrombosis associated with
sirolimus-eluting stent was noticed 2 weeks after the
patient stopped anti-platelet therapy. More recently, a
Sirolimus up-regulates tissue factor (TF) expression in SMCFigure 1
Sirolimus up-regulates tissue factor (TF) expression in SMC. (A). Sirolimus enhances TF expression in a concentra-
tion- and (B) time-dependent manner in human SMC. n = 6, * = p < 0.05 vs. control, ** = p < 0.01 vs. control.Page 3 of 7
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thrombosis related to drug-eluting stents that occurred
several months after coronary intervention [12]. It raises
much concern by the observation that in two patients who
received both a bare metal stent and a sirolimus-eluting
stent, only the drug-eluting stents were closed due to late
stent thrombosis which developed shortly after anti-plate-
let therapy was interrupted, whereas the bare metal stents
in the same patients remained open [12]. This observa-
tion may indicate that sirolimus could exert pro-throm-
botic effects, in particular, when anti-platelet therapy was
discontinued. Adverse effects of sirolimus related to
thrombosis have been documented in vitro experiments
and also in vivo in an animal model [28-30]. Sirolimus has
been reported to inhibit endothelium-dependent relaxa-
tions in porcine coronary arteries [28]. Inhibition of
endothelialization by sirolimus has also been shown in
human necropsy specimens and in animal models
[31,32]. Moreover, stimulation or facilitation of platelet
aggregation and secretion by sirolimus has also been dem-
onstrated [29]. The pro-thrombotic effect of sirolimus was
also demonstrated in a rat model of synthetic vascular
grafts [30]. In our present study, we demonstrated that in
human SMC, sirolimus increased TF protein level at a low
concentration i.e. 0.1 ng/ml, which reached the maximal
effect at 5 ng/ml (Fig. 1A). This concentration is in the
range of clinical settings, since systemic level of sirolimus
was reported to be in the range of 1~2 ng/ml within the
first hours after CYPHER stent placement [33]. The con-
centration in the vascular wall is expected to be higher.
The stimulation of TF expression by sirolimus (20 ng/ml)
is also time-dependent (24 hours, 270% increase above
control, Fig. 1B, n = 6, p < 0.01). Our result is in line with
a recent observation by Guba et al., showing that
sirolimus stimulates TF expression in human endothelial
cells [34].
Fluvastatin inhibits TF expression in SMCigure 2
Fluvastatin inhibits TF expression in SMC. In human saphenous vein SMC (HSVSMC, panel A, n = 4) as well as in human 
aortic SMC (HAoSMC, panel B, n = 4) sirolimus (20 ng/ml, 24 hours) up-regulated TF expression which was significantly inhib-
ited by fluvastatin (1 µmol/L). Basal activity of RhoA was not influenced by sirolimus (20 ng/ml, n = 3, panel C), while the basal 
activity of mTOR was fully inhibited by sirolimus (20 ng/ml, 1 hour, n = 3, panel D). * = p < 0.01 vs. control, † = p < 0.05 vs. 
sirolimus.Page 4 of 7
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sirolimus (20 ng/ml, 24 hours) was fully inhibited by the
HMG-CoA reductase inhibitor fluvastatin (1 µmol/L) in
human saphenous vein (Fig. 2A) and aorta SMCs (Fig. 2B)
(n = 4, p < 0.05). Fluvastatin alone, however, did not sig-
nificantly affect the basal TF expression in the cells (Fig.
2A and Fig. 2B). Statins exert many effects on vascular cells
via inhibition of RhoA [20,35]. It is, however, unlikely
that this mechanism explains the inhibitory effect of TF
expression by fluvastatin. Firstly, a significant basal activ-
ity of RhoA was present in SMC (Fig. 2C), which was,
however, not further stimulated by sirolimus (20 ng/ml)
over 60 minutes (Fig. 2C). Secondly, fluvastatin alone did
not inhibit basal TF expression (Fig. 2A and 2B), suggest-
ing that basal TF expression is not mediated by RhoA.
Results of our previous studies and others demonstrated
that besides RhoA, p38mapk is also a positive regulator of
TF expression in vascular endothelial cells and SMCs [15-
17]. Our present study showed that no basal activity of
p38mapk could be detected, and sirolimus (20 ng/ml,
over 60 minutes) did not activate p38mapk in SMC. These
results suggest that sirolimus enhances TF expression not
through p38mapk and RhoA. Although the exact mecha-
nism of statin-induced inhibition of TF expression by
sirolimus is still obscure under this condition, our results
support the clinical benefit of statins in patients with cor-
onary stenting.
It is well described that sirolimus is a natural immunosup-
pressant which interferes with cellular functions via block-
ade of the protein kinase, mTOR [8] which further
activates its downstream effector p70s6k by phosphorylat-
ing T389 residue [36]. In our present study, we showed a
significant basal activity of mTOR in SMC as measured by
p70s6k phosphorylation at T389 (Fig. 2D). The activity of
mTOR was abolished by sirolimus (20 ng/ml, 1 hour
treatment, Fig. 2D). Whether this data suggest an inhibi-
tory effect of mTOR on TF expression needs further inves-
tigation. Further results demonstrate that fluvastatin does
not reverse the inhibition of mTOR i.e. phosphorylation
of p70s6k at T389 by sirolimus, nor it had any effect on
basal mTOR activity in the cells (Fig. 2D), suggesting that
statin inhibits TF expression not through regulation of
mTOR.
Despite increased TF protein expression by sirolimus in
SMC, the activity of TF released from SMC into the culture
medium was not enhanced by sirolimus (Fig. 3). For the
validity of the method, a control experiment using
endothelial cells was performed. Endothelial cells had
much lower TF activity than SMC (p < 0.0001; n = 6–9),
that was significantly enhanced by TNF-α (20 ng/ml; 5
hours, p < 0.05, n = 9, Fig. 3)
Conclusion
Taken together, our results demonstrate that although
sirolimus stimulates TF expression in human SMC, it does
not enhance TF activity released from the cells. The results
support the safe profile of CYPHER stents observed by
clinical trials. The inhibition of TF expression by fluvasta-
tin favors clinical use of statins in patients undergoing cor-
onary stenting.
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Sirolimus does not stimulate TF release and activity from MCFigure 3
Sirolimus does not stimulate TF release and activity 
from SMC. Human SMC released much higher TF activity 
into the culture medium than endothelial cells (HUVECs) (p 
< 0.0001, n = 6–9). TF activity released from SMC was not 
further increased by sirolimus (20 ng/ml, 24 hours). The TF 
activity released from HUVECs was significantly stimulated 
by TNF-α (20 ng/ml; 5 hours, p < 0.05, n = 9).Page 5 of 7
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